SynthesisAnnals of surgical oncology2018
Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 7 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Laparoscopic Versus Open Pancreatoduodenectomy for Periampullary Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of gastrointestinal cancer · 2024Pooled it
- Differences in Lymph Node Metastases Patterns Among Non-pancreatic Periampullary Cancers and Histologic Subtypes: An International Multicenter Retrospective Cohort Study and Systematic Review.Annals of surgical oncology · 2024Pooled it
- Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review.Annals of surgical oncology · 2024Pooled it
- The clinical implication of minimally invasive versus open pancreatoduodenectomy for non-pancreatic periampullary cancer: a systematic review and individual patient data meta-analysis.Langenbeck's archives of surgery · 2023Pooled it
- Evaluation of Systemic Treatments of Small Intestinal Adenocarcinomas: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Clinical practice guidelines for duodenal cancer 2021.Journal of gastroenterology · 2022Guideline
- Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.International journal of clinical oncology · 2021Pooled it
- Ferumoxtran-10-enhanced MRI for pre-operative metastatic lymph node detection in pancreatic, duodenal, or periampullary adenocarcinoma.European radiology · 2024Trial
- Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.Frontiers in immunology · 2023Trial
- Muir-Torre syndrome in a patient with advanced duodenal carcinoma.Clinical journal of gastroenterology · 2026Article
- The role of adjuvant chemotherapy in small bowel adenocarcinomas.The oncologist · 2026Article
- Clinical practice guidelines for duodenal cancer 2025.Journal of gastroenterology · 2026Review
- Limited (pancreas-sparing) surgical resections for non-ampullary duodenal neoplasms: indications, surgical techniques and outcomes.Updates in surgery · 2026Article
- Tumours of the duodenum and the ampulla of Vater: An overview of the key criteria for their classification, pathogenesis, and molecular assessment.Virchows Archiv : an international journal of pathology · 2026Review
- Optimizing postoperative prognostication in duodenal adenocarcinoma: a multicenter study with external validation.The oncologist · 2026Article
- Biology Over Imaging: Duodenal Adenocarcinoma Recurrence Presenting as a Pancreatic Head Mass in Lynch Syndrome.Cureus · 2026Article
- Diagnostic performance of CT-based node reporting and data system (Node-RADS) for regional lymph node metastasis in periampullary cancer.Abdominal radiology (New York) · 2026Article
- Enhanced survival in resectable duodenal adenocarcinoma with adjuvant chemotherapy: evidence from a retrospective study.Frontiers in oncology · 2026Article
- Synchronous medullary carcinoma of the pancreas and non-ampullary duodenal adenocarcinoma.Archive of clinical cases · 2026Article
- Pancreas-preserving segmental duodenectomy for duodenal malignancy: two case reports.Frontiers in oncology · 2026Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuodenal adenocarcinoma (DA) is a rare tumor for which survival data per treatment modality and disease stage are unclear. This systematic review and meta-analysis aims to summarize the current literature on patient outcome after surgical, (neo)adjuvant, and palliative treatment in patients with DA.
methodsA systematic search was performed according to the preferred reporting items for systematic reviews and meta-analyses guidelines, to 25 April 2017. Primary outcome was overall survival (OS), specified for treatment strategy or disease stage. Random-effects models were used for the calculation of pooled odds ratios per treatment modality. Included papers were also screened for prognostic factors.
resultsA total of 26 observational studies, comprising 6438 patients with DA, were included. Of these, resection with curative intent was performed in 71% (range 53-100%) of patients, and 29% received palliative treatment (range 0-61%). The pooled 5-year OS rate was 46% after curative resection, compared with 1% in palliative-treated patients (OR 0.04, 95% confidence interval [CI] 0.02-0.09, p < 0.0001). Both segmental resection and pancreaticoduodenectomy allowed adequate assessment of lymph node involvement and resulted in similar OS. Lymph node involvement correlated with worse OS (pooled 5-year survival rate 21% for nodal metastases vs. 65% for node-negative disease; OR 0.17, 95% CI 0.11-0.27, p < 0.0001). In the current literature, no survival benefit for adjuvant therapy after curative resection was found.
conclusionResection with curative intent, either pancreaticoduodenectomy or segmental resection, and lack of nodal metastases, favors survival for DA. Further studies exploring multimodality (neo)adjuvant therapy are warranted to investigate their benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.